A Study to Investigate the Effect of Different Doses of AZD0780 on Low-Density Lipoprotein Cholesterol (LDL-C) Levels Compared with Placebo and its Safety and Tolerability in Participants 18 to 75 Years of Age with Dyslipidemia - PURSUIT

Study identifier:D7960C00006

ClinicalTrials.gov identifier:NCT06173570

EudraCT identifier:N/A

CTIS identifier:2023-506197-12-00

Recruiting

Official Title

A Phase IIb, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AZD0780 in Participants with Dyslipidemia

Medical condition

Dyslipidemia

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD0780, Placebo

Sex

All

Estimated Enrollment

375

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 19 Jan 2024
Estimated Primary Completion Date: 13 Nov 2024
Estimated Study Completion Date: 27 Nov 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

AstraZeneca K.K.

Inclusion and exclusion criteria